| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $14.5M | +465.0% | +2613.4% |
| SG&A Expense | $1.3M | -4.8% | -27.1% |
| Operating Income | -$15.8M | -303.0% | -587.0% |
| Pre-tax Income | -$15.7M | -313.6% | -590.4% |
| Net Income | -$15.7M | -313.5% | -590.3% |
| EPS (Basic) | -$8.20 | -312.1% | -300.0% |
| EPS (Diluted) | -$8.20 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.1M | -24.4% | +396.5% |
| Current Assets | $11.7M | -20.7% | +410.5% |
| Total Assets | $92.0M | -4.9% | +3929.0% |
| Current Liabilities | $2.6M | +37.7% | +94.7% |
| Total Liabilities | $14.6M | +3.2% | +995.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.0M | — | — |
| Financing Cash Flow | $7.3M | — | — |
| -312.1% |
| -300.0% |
| $7.3M |
| +5.5% |
| +664.5% |